financetom
Business
financetom
/
Business
/
Update: C2C Metals Up 7.1% as It Acquires Uranium-Vanadium Properties in Colorado
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: C2C Metals Up 7.1% as It Acquires Uranium-Vanadium Properties in Colorado
Oct 23, 2024 9:20 AM

11:57 AM EDT, 10/23/2024 (MT Newswires) -- C2C Metals ( CTCGF ) said on Wednesday it acquired five uranium-vanadium properties comprising about 5,400 acres in the Colorado portion of the Uravan Mining District.

The company said it paid US$66,760 in cash, $90,000 in shares and granted the sellers a 1% net smelter royalty.

C2C said the properties were selected based on historical information from previous exploration, indicating that specific targets hosted either drill-defined historical estimated uranium and vanadium mineral resources, or areas specifically targeted for drilling by historical operators.

C2C shares were last seen up $0.01 to $0.15 on the Canadian Securities Exchange.

Price: 0.15, Change: +0.01, Percent Change: +7.14

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AGBA, Triller Complete All Steps for Merger, Awaiting Final Nasdaq Approval
AGBA, Triller Complete All Steps for Merger, Awaiting Final Nasdaq Approval
Oct 11, 2024
07:44 AM EDT, 10/11/2024 (MT Newswires) -- AGBA (AGBA) and Triller said Friday they have finalized all necessary steps for their upcoming merger, expected to be completed around Oct. 14, pending final Nasdaq approval. As part of the merger, AGBA will undergo a reverse stock split at a 4-to-1 ratio to comply with Nasdaq requirements. The reverse split will be...
Sagimet Biosciences' MASH Drug Meets Main, Secondary Goals in Phase 2b Study
Sagimet Biosciences' MASH Drug Meets Main, Secondary Goals in Phase 2b Study
Oct 11, 2024
07:41 AM EDT, 10/11/2024 (MT Newswires) -- Sagimet Biosciences ( SGMT ) said Friday that its experimental drug, denifanstat, used to treat certain metabolic-dysfunction-associated steatohepatitis patients, met its primary and secondary endpoints in a phase 2b study. The study showed that patients treated with the denifanstat showed statistically significant and clinically meaningful improvements in disease activity, MASH resolution, and fibrosis...
Top Premarket Decliners
Top Premarket Decliners
Oct 11, 2024
07:38 AM EDT, 10/11/2024 (MT Newswires) -- Hesai Group ( HSAI ) shares fell nearly 10% pre-bell Friday, erasing Thursday's gains. SKYX Platforms ( SKYX ) shares dropped more than 9% following a 2.4% loss in the previous session. Vroom (VRM) shares were down more than 8%, adding to Thursday's 2.3% drop. Price: 4.83, Change: -0.53, Percent Change: -9.89 ...
--Street Color: Meta Platforms Removes Fake Accounts That Targeted Russian-Speaking Audiences in Moldova
--Street Color: Meta Platforms Removes Fake Accounts That Targeted Russian-Speaking Audiences in Moldova
Oct 11, 2024
07:37 AM EDT, 10/11/2024 (MT Newswires) -- Price: 584.88, Change: +1.05, Percent Change: +0.18 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved